Evidence map›Paper›PMID 37990682›Full record

ArticleObesity pillars2023

Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study.

Jesse Richards, Neha Bang, Erin L Ratliff, Maria A Paszkowiak, Zhamak Khorgami, Sahib S Khalsa, W Kyle Simmons

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Obesity pillars, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 4 pooled it
25.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 4 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Review
  9. Observational
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Observational
  19. Review
  20. Misrepresentation of semaglutide in social media.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Jesse RichardsDepartment of Internal Medicine, University of Oklahoma School of Community Medicine, Tulsa, OK, USA.
Neha BangDepartment of Internal Medicine, University of Oklahoma School of Community Medicine, Tulsa, OK, USA.
Erin L RatliffDepartment of Pharmacology & Physiology, Oklahoma State University, Center for Health Sciences, Tulsa, OK, USA.
Maria A PaszkowiakDepartment of Internal Medicine, University of Oklahoma School of Community Medicine, Tulsa, OK, USA.
Zhamak KhorgamiDepartment of Internal Medicine, University of Oklahoma School of Community Medicine, Tulsa, OK, USA.
Sahib S KhalsaLaureate Institute for Brain Research, Tulsa, OK, USA.
W Kyle SimmonsDepartment of Pharmacology & Physiology, Oklahoma State University, Center for Health Sciences, Tulsa, OK, USA.
University of Oklahoma · USImaging Center · USLaureate Institute for Brain Research · USOklahoma State University Center for Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Binge eating disorder (BED) is the most common eating disorder, and yet only one pharmacotherapy (lisdexamfetamine), which has known abuse-potential, is FDA-approved. Topiramate is also commonly prescribed off-label for binge eating but has many contraindications. In contrast, the glucagon-like peptide-1 (GLP1) analog semaglutide has profound effects on central satiety signaling leading to reduced food intake, and has been approved for the treatment of obesity based on its efficacy and safety profile. Semaglutide would thus seem to be a potential candidate for the treatment of BED. Methods: This open-label study examined the effects of semaglutide on Binge Eating Scale (BES) scores in individuals with BED. Patients were divided into three groups: those prescribed semaglutide, those prescribed either lisdexamphetamine or topiramate, and those prescribed a combination of semaglutide with lisdexamphetamine or topiramate. Results: Patients receiving semaglutide only exhibited greater reductions in BES scores compared to the other groups. Combined pharmacotherapy with both semaglutide and the other anti-obesity medications did not result in greater reductions in BES scores compared to the semaglutide-only group. Findings were similar in patients with moderate/severe BED, as well as the full sample. Conclusion: The therapeutic effects of semaglutide in binge eating disorder warrant further investigation.

Indexed as

Binge eating disorderGLP-1 agonistSemaglutide

Identifiers

PMID37990682
PMCPMC10661993
OpenAlexW4384936477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.